Cervical Cancer Screening
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB002 alerts
Get alerted when Policy CPCPLAB002 changes without checking for updates manually.
Monitor payer policy activity
Defines reimbursement and laboratory coding criteria for cervical cancer screening tests (Pap cytology, high-risk HPV testing, and co-testing) for BCBS Oklahoma members and provider billing expectations.
Added new CPT code 87626 effective 01/01/2025.
Reimbursement criterion for immunocompromised individuals updated to allow annual cytology for individuals of all ages and co-testing every 3 years for those 30 and older.
Added nucleic acid testing for HPV-16 and HPV-18 for HPV positive / cytology negative individuals.
Clarified recommendations for individuals over 65: routine screening not reimbursable if adequate prior screening documented.
Added CPT code 0502U to the code list.
Medically Necessary and Not Medically Necessary Criteria
Medically necessary coverage criteria
Covered when meeting the specified age- and risk-based criteria:
Immunocompromised definition implied by guideline references.
Cervical cancer screening for individuals less than 21 years of age is not reimbursable except as specified elsewhere in this policy. Claims for routine screening in this age group will be denied unless a specific exception described in other reimbursement criteria applies.
Cervical cancer screening is not reimbursable for individuals who have undergone surgical removal of the uterus and cervix and who have no history of cervical cancer or pre‑cancer. This exclusion applies at any age.
Routine cervical cancer screening for individuals over 65 years of age who are not considered high‑risk is not reimbursable when an adequate screening history is documented. Adequate screening history is defined as either (a) three consecutive negative Pap smears, or (b) two consecutive negative HPV tests within 10 years with the most recent test within 5 years.
Procedure, Laboratory Codes and Definitions
Billing, Documentation, and Denial Risk Guidance
Claims documentation and coding requirements
Providers are responsible for submission of accurate documentation of services performed. Providers must submit claims using HIPAA-approved code sets and follow industry standard coding guidelines (e.g., Uniform Billing Editor, AMA CPT, HCPCS, ICD-10-CM/PCS, NDCs, DRG rules, CMS NCCI). Claims are subject to code-edit protocols and clinical review; upon request providers should supply supporting documentation.
- Use valid code combinations from HIPAA-approved code sets.
- Follow industry coding guidance (CPT, HCPCS, ICD-10, NDC, CMS NCCI/CCI, DRG).
- Be prepared to provide additional documentation upon request.
Code listing and prior authorization note
The codes listed are provided for reference only. Inclusion does not guarantee coverage or payment; verify member benefits, applicable plan documents, and provider contract terms. Prior authorization may be required by some plans — check eligibility and prior authorization rules before rendering services.
Denial triggers
Denial risk increases when services fall outside stated reimbursement criteria — for example, routine cervical cancer screening for individuals over 65 who are not high risk with an adequate screening history, screening after hysterectomy when there is no history of cervical cancer or pre-cancer, or screening for individuals under 21 outside specified exceptions. Claims lacking adequate clinical history or documentation to demonstrate medical necessity may be denied.
- Routine screening not reimbursable for >65 with adequate screening history (see definitions in policy).
- Screening not reimbursable after total hysterectomy without prior cervical cancer/pre-cancer.
- Screening for individuals <21 generally not reimbursable unless specific exceptions apply.
- Insufficient documentation of medical necessity or history may trigger denial.
Clinical Background and Rationale
Cervical cancer screening uses cytology (Papanicolaou/Pap smear), high‑risk HPV testing, or both (co‑testing) to detect precancerous changes. This policy aligns reimbursement with age‑ and risk‑based guideline recommendations: for immunocompromised individuals, annual cytology or co‑testing every 3 years for those ≥30 may be reimbursable; for ages 21–29, Pap smear every 3 years is reimbursable; for ages 30–65, any one of Pap every 3 years, primary high‑risk HPV testing every 5 years, or co‑testing every 5 years may be reimbursable. For HPV positive / cytology negative results, reflex nucleic acid testing for high‑risk strains HPV‑16 and HPV‑18 may be reimbursable. National guideline bodies inform these intervals and the policy’s risk‑stratified approach.
Terms and Policy-Specific Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.